An Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition

Trial Profile

An Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes; Coronary artery disease; Peripheral arterial disorders; Stroke
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 Sep 2016 Results (n=44) assessing effect of autologous platelet transfusion on platelet inhibition in ticagrelor and clopidogrel treated subjects, published in the Journal of Thrombosis and Haemostasis.
    • 23 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Feb 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top